Information for Retatrutide
Retatrutide, a potent gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptor agonist, holds immense potential for researchers exploring the intricacies of hunger-regulating hormones.
Research Certificates of Analysis
12.50mg
Task #42394
Batch #05012024
05/08/2024
GMP Certificates of Analysis
11mg
Batch #PKRET10924
09/11/2024
Retatrutide Peptide Structure
Source: PubChem
Sequence: Gly- Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Molecular Formula: C62H98N15O22
Molecular Weight: 1419.556 g/mol
PubChem CID: 108101
What Is Retatrutide?
Encourages weight loss in patients with obesity1
Improves glycaemic control in people with type 2 diabetes2
Decreases HbA1c levels3
Delays gastric emptying4
Regulates blood glucose levels1,5
Research Studies
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–Hormone-Receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine/The New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/nejmoa2301972
- Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., & Coskun, T. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet, 402(10401), 529–544. https://doi.org/10.1016/s0140-6736(23)01053-x
- Ray, A. (2023). Retatrutide: a triple incretin receptor agonist for obesity management. Expert Opinion on Investigational Drugs, 32(11), 1003–1008. https://doi.org/10.1080/13543784.2023.2276754
- Urva, S., O’Farrell, L., Du, Y., Loh, M. T., Hemmingway, A., Qu, H., Alsina‐Fernandez, J., Haupt, A., Milicevic, Z., & Coskun, T. (2023). The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes, Obesity & Metabolism/Diabetes, Obesity and Metabolism, 25(9), 2784–2788. https://doi.org/10.1111/dom.15167
- Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., Pirro, V., Wainscott, D. B., Willard, F. S., Abernathy, M., Morford, L., Du, Y., Benson, C., Gimeno, R. E., Haupt, A., & Milicevic, Z. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234-1247.e9. https://doi.org/10.1016/j.cmet.2022.07.013
Product Usage
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
